Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)
Neoadjuvante FOLF(IRIN)OX-Chemotherapie bei resektablem Pankreasadenokarzinom: multizentrische randomisierte nichtvergleichende Phase-II-Studie (PANACHE01 FRENCH08 PRODIGE48)
Journal of Clinical Oncology · 10.06.2025 · 43 (17) · 1984-1996
DOI: 10.1200/jco-24-01378 ↗Auf einen Blick
Bei 153 Patient:innen mit resektablem Pankreasadenokarzinom war mFOLFIRINOX im perioperativen Setting mit hoher Durchführbarkeit und guten onkologischen Ergebnissen verbunden. Arm 2 (FOLFOX) wurde nach Interimsanalyse wegen fehlender Wirksamkeit beendet.
Fragestellung
Wie machbar und wirksam sind neoadjuvante mFOLFIRINOX- oder FOLFOX-Regime bei resektablem Pankreasadenokarzinom?
Methode
Phase-II-Studie; 153 Patient:innen mit resektablem Pankreasadenokarzinom an 28 französischen Zentren; Randomisierung 2:2:1 zu 4 Zyklen mFOLFIRINOX, FOLFOX oder sofortiger Operation; Rekrutierung Februar 2017 bis Juli 2020.
Ergebnisse
In Arm 1 erfüllte die Studie das primäre Ziel. Vollständige Sequenz: 70,8 % (90 %-KI 60,8–79,6) Arm 1, 68 % (90 %-KI 55,5–78,8) Arm 2. 1-Jahres-OS: 84,3 % vs. 71,4 %. 1-Jahres-EFS: 51,4 %, 43,1 %, 38,7 %.
Einschränkungen
Arm 2 wurde nach Interimsanalyse wegen fehlender Wirksamkeit beendet.
Schlussfolgerung der Autor:innen
Die Machbarkeit und Wirksamkeit von mFOLFIRINOX im perioperativen Setting wurden hinsichtlich Abschluss der therapeutischen Sequenz und onkologischer Ergebnisse bestätigt.
Kernaussagen
- mFOLFIRINOX erfüllte das primäre Ziel
- 1-Jahres-OS: 84,3 % unter mFOLFIRINOX
- Arm 2 wegen fehlender Wirksamkeit gestoppt
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2025. Verfasst von Lilian Schwarz und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery, Rouen University Hospital, Rouen, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Adenocarcinoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Despite limited RCTs, neoadjuvant chemotherapy (NAC) shows promise for resectable pancreatic adenocarcinoma (rPAC). Few prospective results are available on completing the full therapeutic sequence and oncologic outcomes with NAC. METHODS The PANACHE01-PRODIGE48 phase II trial randomly assigned 153 patients with rPAC (2:2:1) to four cycles of NAC (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin [mFOLFIRINOX], arm 1; leucovorin, fluorouracil, and oxaliplatin [FOLFOX], arm 2) or up-front surgery (control) across 28 French centers (February 2017-July 2020). The primary objective was to evaluate the feasibility and efficacy of these NAC regimens. Two binary primary end points included 1-year overall survival (OS) postrandomization and the rate of patients completing the full therapeutic sequence. Event-free survival (EFS) assessed time to failure, defined as progression before surgery, unresectable/metastatic disease at surgery, recurrence, or death. RESULTS The primary objective was achieved for arm 1. In the intention-to-treat population, 70.8% (90% CI, 60.8 to 79.6) and 68% (90% CI, 55.5 to 78.8) completed the therapeutic sequence in arm 1 and arm 2, respectively. Within 12 months postrandomization, 84.3% (90% CI, 75.3 to 90.9) and 71.4% (90% CI, 59.0 to 81.8) of the patients were alive in arm 1 and arm 2, respectively. Treatment was safe and well-tolerated in both NAC arms. Arm 2 was stopped after interim analysis for lack of efficacy (H0 rejection for 1-year OS). One-year EFS rates were 51.4% (95% CI, 41.0 to 64.3), 43.1% (95% CI, 31.3 to 59.5), and 38.7% (95% CI, 24.1 to 62.0) in arm 1, arm 2, and control arm, respectively. CONCLUSION The feasibility and efficacy of mFOLFIRINOX in the perioperative setting are confirmed concerning therapeutic sequence completion and oncologic outcomes, supporting ongoing trials (PREOPANC3, Alliance AO21806). Further research is needed to identify patients who benefit from NAC (ClinicalTrials.gov identifier: NCT02959879 ; EudraCT: 2015-001851-65).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Digestive Surgery, Rouen University Hospital, Rouen, France.
- Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Normandie University, Rouen, France.
- Department of Hepato-Gastroenterology, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
- Methodology and Quality of Life in Oncology Unit, Besançon University Hospital, Besançon, France.
- EFS, INSERM, UMR RIGHT, Université de Franche-Comté, Besançon, France.
- Digestive Oncology Department, Centre Hospitalier Universitaire Robert Debré, Reims, France.
ORCID-Profile: Lilian Schwarz, Jean-Baptiste Bachet, Olivier Bouché, Eric Assenat, Julien Taieb, Anthony Turpin, Stephanie Truant, Antonio Sa Cunha
Zitieren
APA
Schwarz, L., Bachet, J. B., Meurisse, A., Bouché, O., Assenat, E., Piessen, G., Hammel, P., Regenet, N., Taieb, J., Turrini, O., Paye, F., Turpin, A., Souche, F. R., Laurent, C., Kianmanesh, R., Michel, P., Vernerey, D., Mabrut, J. Y., Turco, C., …, & PANACHE01-FRENCH08-PRODIGE48 Investigators (2025). Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study). Journal of Clinical Oncology, 43(17), 1984-1996. https://doi.org/10.1200/jco-24-01378
Vancouver
Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, et al. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study). Journal of Clinical Oncology. 2025;43(17):1984-1996. doi:10.1200/jco-24-01378
BibTeX
@article{Schwarz2025,
author = {Schwarz, Lilian and Bachet, Jean-Baptiste and Meurisse, Aurelia and Bouché, Olivier and Assenat, Eric and Piessen, Guillaume and Hammel, Pascal and Regenet, Nicolas and Taieb, Julien and Turrini, Olivier and Paye, Francois and Turpin, Anthony and Souche, Francois-Regis and Laurent, Christophe and Kianmanesh, Reza and Michel, Pierre and Vernerey, Dewi and Mabrut, Jean-Yves and Turco, Celia and Truant, Stephanie and Sa Cunha, Antonio and PANACHE01-FRENCH08-PRODIGE48 Investigators, PANACHE01-FRENCH08-PRODIGE48 Investigators},
title = {Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {17},
pages = {1984--1996},
doi = {10.1200/jco-24-01378}
}
EUVIMED